Impact Biomedical and Global Research & Discovery Group Represent a Thriving Example in the Shift in the Biomedical Innovation and Investment Industry
Retrieved on:
Tuesday, February 14, 2023
Investment, Patent cliff, Development, Intellectual property, World Health Organization, Safety, Philosophy, Patient, Biomedical Research, Research, Risk, ZS, Discovery, Discovery and development of non-nucleoside reverse-transcriptase inhibitors, Pharmacy, Phase II, Global Research, FDA, Growth, Volunteering, J. P. Morgan, HAVEN, ZS Associates, DiscoverIE Group, Medical device, Renewable energy, Pharmaceutical industry, Generic drug
WINTER HAVEN, Fla., Feb. 14, 2023 /PRNewswire/ -- Impact BioMedical, in concert with its research partner Global Research and Discovery Group, find themselves in the right place at the right time as the biomedical investment industry shifts toward Discovery-phase funding in biomedical research, licensing and intellectual property and away from waiting until Phase 2 or Phase 3 clinical trials. This shift sets the partnering companies on a path that could help stabilize the future of the industry.
Key Points:
- This shift sets the partnering companies on a path that could help stabilize the future of the industry.
- That early investment in biomedical research is on the rise should not come as a surprise to those who have watched the market develop over time.
- The one bright spot was that more investment came early in the research process, which, since the early 2000s has taken larger shares of the investment dollar.
- "Now, more than ever, Discovery is the key to the immediate future of biomedical innovation."